Presentation + Paper
5 March 2021 Monitoring cancer cell surface receptor expression during anti-angiogenesis therapy in vivo
Boyu Meng, Rendall R. Strawbridge, Kenneth Tichauer, Kimberley S. Samkoe, Scott C. Davis
Author Affiliations +
Abstract
Concurrent administration of cancer therapeutics with tumor vasculature targeting treatment has been shown to improve overall survival in multiple human cancer types, as such combinations aim to destroy different compartments of tumors. Anti-angiogenesis therapeutics designed to inhibit tumor induced vessel sprouting have also been shown to re-model the tumor vasculature through a transient vessel normalization effect, which leads to improved perfusion of oxygen and drug in tumor. However, the effects that this normalized vasculature has on the availability of cancer receptor, such as EGFR, is unknown. Herein, we examined the use of MRI-PAFT to estimate cancer surface receptor availability in response to anti-angiogenesis therapy, using MRI-coupled paired agent fluorescence tomography. Bevacizumab treated tumors showed increase in RA compared to control tumors, but this was not statistically significant.
Conference Presentation
© (2021) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Boyu Meng, Rendall R. Strawbridge, Kenneth Tichauer, Kimberley S. Samkoe, and Scott C. Davis "Monitoring cancer cell surface receptor expression during anti-angiogenesis therapy in vivo", Proc. SPIE 11625, Molecular-Guided Surgery: Molecules, Devices, and Applications VII, 116250Q (5 March 2021); https://doi.org/10.1117/12.2583237
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Magnetic resonance imaging

Surgery

Tumors

Gadolinium

Imaging systems

Image segmentation

Luminescence

RELATED CONTENT


Back to Top